VivoSeq
Oncology

Rectal Cancer Patients

1

Pipeline Programs↗

9

Active Trials↗

1

Companies Involved↗

Rectal Cancer Patients is an early-stage landscape with 1 program across 1 company. The most active players are Henry Smith.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Henry Smith

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

PD-1 Blocking Antibody

Sun Yat-sen University

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

20

clinical trials

Completed6 · 30%
Active, not recruiting5 · 25%
Unknown status4 · 20%
Recruiting3 · 15%
Withdrawn1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Recruiting·NNanoEcho AB·Phase 2·NCT06693375·12 enrolled
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
Recruiting·VVejle Hospital·Phase 3·NCT04095299·162 enrolled
A Phase I Study of the Safety and Efficacy of a Modified Vaccinia Virus (BT-001) Delivered by Endoscopic Intra-tumoural Injection Followed by Systemic Antiprogammed Death-1 (Anti-PD-1) Antibodies in Patients With Localised Rectal Cancer With Proficient Mismatch Repair (pMMR)
Recruiting·—·Phase 1·NCT07687875·20 enrolled
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
Active, not recruiting·PProf. Dr. med. Claus Rödel·Phase 3·NCT04246684·702 enrolled
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Active, not recruiting·—·Phase 2·NCT03921684·29 enrolled
Organ Preservation in Early Rectal Cancer Patients
Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03548961·19 enrolled
A Phase II Clinical Study of Long-Course Concurrent Chemoradiotherapy Combined With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer With Sphincter-Preservation Demand
Active, not recruiting·HHarbin Medical University·Phase 2·NCT07687433·43 enrolled
Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study
Active, not recruiting·HHarbin Medical University·Phase 2·NCT07663071·44 enrolled
Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection
Not yet recruiting·TTehran University of Medical Sciences·Phase 1·NCT06536712·20 enrolled
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Completed·CChinese Academy of Medical Sciences·Phase 1·NCT01268943·18 enrolled
Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients
Completed·GGoethe University·Phase 1·NCT04942626·12 enrolled
Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
Completed·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT01554059·25 enrolled
Non-OpeRative MANagement of Rectal Cancer Patients
Completed·KKangbuk Samsung Hospital·Phase 2·NCT04696757·18 enrolled
Pilot Randomized Evaluation of Butyrate Irrigation Before Ileostomy Closure on the Colonic Mucosa in Rectal Cancer Patients (BUTYCLO)
Completed·IInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta·Phase 2·NCT04795180·45 enrolled
Impact Of Metformin In Rectal Cancer Patients
Completed·MMinia University·Phase 2/3·NCT06728982·85 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)